Diabetic Polyneuropathy and Benfotiamine

During episodes of hyperglycemia, unlike most other cell types, the neurons and Schwann cells of the peripheral nervous system are unable to successfully prevent the rise of their internal glucose levels and, as a consequence, are damaged. This mechanism was described by Michael Brownlee, in his seminal paper, The Pathobiology of Diabetic Complications.  Increased levels of intracellular glucose damage these cells by increasing oxidative stress and increasing flux through destructive metabolic pathways.  This results in diabetic polyneuropathy.

Benfotiamine, a high-potency, lipid-soluble form of thiamine (vitamin B1) has been shown to reduce oxidative stress, decrease flux through these destructive pathways and improve the symptoms of diabetic polyneuropathy.

Benfotiamine has also been shown to reverse thiamine deficiency, a well-established consequence of diabetes and cause of polyneuropathy. Unfortunately, the importance of thiamine deficiency in diabetes is generally underappreciated by many clinicians.  Porta et al. make the case that “diabetes might be considered a thiamine-deficient state...”. They argue that diabetes, a disease characterized by impaired carbohydrate processing, is intimately related to thiamine deficiency, a condition that impairs carbohydrate processing.

Hence, the well-established therapeutic benefits achieved with benfotiamine in the treatment of diabetic polyneuropathy are likely the result of the reduction of oxidative stress, the inhibition of destructive metabolic pathways and the reversal of thiamine deficiency in the cells of the peripheral nervous system.

A request from the author:
Have any of your patients who have taken NeuRemedy experienced any benefits in addition to improvement in their neuropathic symptoms? If so, I would like to know. Please contact me at rhm123@gmail.com or call me at 561-549-9099.

Dr. Mann bust-shotDr. Richard H Mann, DABPS, ret
Chief Scientific Officer & Founder, Realm Labs

If you would like to speak with Dr. Mann about how to improve your outcomes in the treatment of polyneuropathy call 866-634-2745 or email Dr. Mann at realmlabs123@gmail.com

Dr. Mann is the developer of the  NeuRemedy®line of benfotiamine nutritional supplements. NeuRemedy is a safe, proven, and effective nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains in the feet and legs.  Thiamine (vitamin B1) deficiency often accompanies and intensifies these symptoms. The reversal of thiamine deficiency is an important therapeutic goal in the management of these patients.*

The key ingredient in NeuRemedy, benfotiamine, is the most highly bioactive oral form of thiamine available. It rapidly and safely reverses thiamine deficiency, improving the functioning of the nerves in the feet and legs. Each capsule of NeuRemedy contains 150 mg of benfotiamine in a proprietary formulation. Because of its impressive success rate and high safety profile, NeuRemedy was recently licensed in Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.*

NeuRemedy is the leader in the field with thousands of physicians and patients relying each day on its efficacy, purity, safety and rapid onset of action.*

For more information on NeuRemedy:
In the USA contact Realm Labs at 866-634-2745.
In Canada contact OHI at 855-561-4156.

Leave a Reply

Your email address will not be published. Required fields are marked *